Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Incyte

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace The failure of Incyte’s IDO1 inhibitor epacadostat in a trial pairing it with Merck &Co/MSD’s PD-1 inhibitor Keytruda (pembrolizumab) last month seems to have started a chain ... The Incyte trial failure was swiftly followed by a decision by NewLink

Morning brief: Roche raises outlook for 2018, ASCO abstracts revealed and more

Morning brief: Roche raises outlook for 2018, ASCO abstracts revealed and more One of the first companies out of the gate is Incyte - which needs to reassure investors it can salvage lead candidate epacadostat, which recently flopped in a combination trial with Keytruda.

FDA panel undermines Lilly and Incyte’s baricitinib hopes

FDA panel undermines Lilly and Incyte’s baricitinib hopes Mixed review doesn’t bode well in competitive market. An FDA advisory committee backed approval of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis yesterday, but their verdict raises doubts ... In the US, Lilly and Incyte has suggested

Incyte/Merck trial failure bodes ill for IDO class

Incyte/Merck trial failure bodes ill for IDO class Ahead of the weekend, Incyte and partner Merck &Co were rocked by the news that their much-touted cancer immunotherapy combination had failed comprehensively in its first phase III test. ... The pairing of Incyte’s IDO1 inhibitor epacadostat and

Sanofi’s PD-1 inhibitor starts EU review for skin cancer

Sanofi’s PD-1 inhibitor starts EU review for skin cancer In addition to chasing companies in the category with already-marketed drugs - which also include Roche, AstraZeneca and Merck KGaA/Pfizer - Novartis’ PDR001 and INCSHR-1210 from Incyte/Jiangsu Hengrui are

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...